News and Press Releases
Samsung Bioepis Begins Commercialization of BYOOVIZ, Biosimilar to Lucentis (Ranibizumab), in Europe
Samsung Bioepis completes full transfer of commercial rights from Biogen back to Samsung Bioepis for BYOOVIZ BYOOVIZ becomes the fourth biosimilar directly commercialized by Samsung Bioepis in Europe, following EPYSQLI...
Category: Logistics, Other, Pharmaceutical
Posted: January 2, 2026
Eisai presents 4-year Leqembi (lecanemab) open-label extension data from post-hoc sub-group analysis at German neurology congress
Clarity AD open-label extension data show that after four years of continuous lecanemab treatment in apolipoprotein E ε4 (ApoE ε4*) non-carriers and heterozygotes, patients continued to accrue benefit relative to...
Category: Clinical Trials, Other, Pharmaceutical
Posted: November 12, 2025
Horus Pharma announces strategic Agreement to commercialize Formycon’s Aflibercept Biosimilar FYB203 under the brand name Baiama across Key European Markets including its Home Market France
23 October 2025 -- Nice, France -- Horus Pharma, the second largest independent ophthalmological laboratory in France and a leading player in Europe, today announced that it has entered into...
Category: Logistics, Other, Pharmaceutical
Posted: October 23, 2025
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV 10 October 2025 -- Cairo, Egypt; Berlin, Germany; and New York, New York -- IAVI,...
Category: Biotechnology, Drug Delivery, Logistics, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 10, 2025
Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA
6 October 2025 -- London, UK -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, and its long-standing partner Celltrion Inc., a global biopharmaceutical leader, have signed exclusive licensing agreements...
Category: Logistics, Other, Pharmaceutical
Posted: October 6, 2025
European Marketing Application for AVT23, a Proposed Biosimilar to Xolair (omalizumab), Accepted by the European Medicines Agency
6 October 2025 -- London, UK and Reykjavik, Iceland -- Advanz Pharma Holdco Limited, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: October 6, 2025
Capital House, 1st Floor, 85 King William Street, London EC4N 7BL
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon and its partners entered into a settlement and license agreement with Regeneron for FYB203/AHZANTIVE (Aflibercept-mrbb) Pending litigation at the U.S. District Court for the Northern District of West Virginia...
Category: Logistics, Other, Pharmaceutical
Posted: October 2, 2025
Biocon Biologics Secures U.S. Market Entry Date for Bosaya and Aukelso, Denosumab Biosimilars
1 October 2025 -- Bengaluru, India and New Jersey, US -- Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced a settlement and...
Category: Logistics, Other, Pharmaceutical
Posted: October 1, 2025
Biocon House, Semicon Park Electronics City, Phase – II, Hosur Road Bengaluru 560100, Karnataka, India
Leqembi (lecanemab) long-term 36-month open-label extension data from post-hoc sub-group analysis of ApoE ε4 non-carriers and heterozygotes presented at Alzheimer’s disease congress in Switzerland
Clarity AD open-label extension data show three years of continuous lecanemab treatment in apolipoprotein E ε4 (ApoE ε4) non-carrier and heterozygote patients continued to accrue benefit relative to the Alzheimer's...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 29, 2025
Celltrion opens new UK headquarters in Uxbridge, UK
New office located in the heart of Uxbridge underscores Celltrion’s long-term business commitment in the UK 17 June 2025 -- London, UK -- Celltrion UK has officially opened its new...
Category: Clinical Trials, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical
Posted: June 17, 2025
Leqembi® (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorised in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 16, 2025
Exclusive UniSafe® distribution agreement between Owen Mumford and NIPRO exceeds expectations in Japan with new biosimilar launch
6 December 2024 - Oxford, UK – Owen Mumford, a global leader in medical devices, is pleased to announce that its exclusive agreement with Osaka-based NIPRO CORPORATION (NIPRO) to distribute...
Category: Drug Delivery, Manufacturing and Packing
Posted: December 6, 2024
Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term...
Category: BioManufacturing, Biotechnology
Posted: July 10, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Formycon receives FDA approval for FYB203/ AHZANTIVE) (aflibercept-mrbb), a biosimilar to Eylea
1 July 2024, Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licencing partnerKlinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA")approved FYB203/AHZANTIVE (aflibercept-mrbb),...
Category: Pharmaceutical
Posted: July 1, 2024
Formycon reports on the results of the annual general meeting
Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...
Category: BioManufacturing
Posted: June 13, 2024
